Salix information... looks like VRX should dump it. Valeant has said it wants Xifaxan to become the company’s first $1 billion annual revenue brand. On a conference call Tuesday morning, Dr. Ari Kellen, Valeant executive vice president and company group chairman, reiterated that point. “We obviously expect that to be the case,” he said.
In terms of prescriptions, Kellen said Xifaxan was running “north of 12,000 a week” and expects to see 50 percent growth in prescriptions this year.
Some analysts began to express concerns about Xifaxan after Valeant Executive Vice President
A potential breakthrough in spinal cord and optic nerve injury treatment
Eminent acquires promising Nevada gold project
BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide
NervGen Pharma: Proof that NVG-291 works?